Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$6.5 - $10.77 $78,000 - $129,240
12,000 New
12,000 $81,000
Q1 2022

May 18, 2022

BUY
$14.73 - $35.25 $176,760 - $423,000
12,000 New
12,000 $235,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $538M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Baader Bank Aktiengesellschaft Portfolio

Follow Baader Bank Aktiengesellschaft and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baader Bank Aktiengesellschaft, based on Form 13F filings with the SEC.

News

Stay updated on Baader Bank Aktiengesellschaft with notifications on news.